Postinflammatory hyperpigmentation - Hîperpîgmentasyona Postinflammatory
Hîperpîgmentasyona Postinflammatory (Postinflammatory hyperpigmentation) rewşek çermî ye ku bi zêdebûna rengdêra di çerm de piştî iltîhaba çerm tê xuyang kirin. Hîperpîgmentasyona postinflammatory (postinflammatory hyperpigmentation) dikare ji ber dirêjbûna tavê, iltîhaba, an birînên çerm ên din, tevî yên ku bi pizrikan ve girêdayî ne, çêbibe. Kesên ku rengê çermê wan tarîtir in, bi gelemperî bi tîrêjên zêde yên tavê re meyla hîperpîgmentasyonê ne.
☆ AI Dermatology — Free Service
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
Di encamên 2022-an de Stiftung Warentest ji Almanyayê, razîbûna xerîdar bi ModelDerm tenê ji şêwirmendên telemedicine drav hindik hindiktir bû.
relevance score : -100.0%
ReferencesPostinflammatory hyperpigmentation (PIH) pirsgirêkek çermê ye ku pir caran piştî iltîhabê çermê an birîndarî çêdibe. Ev pir caran demek dirêj dimîne û di mirovên ku rengê çermê wan tarî ye (Fitzpatrick skin types III–VI) de zêde xweşî dike. Heke her çend pir caran xweş dibe, dikare demek dirêj bibe; ji ber vê yekê, dermankirin pir caran ji bo demek dirêj hewce dibe. Tevlihevkirina dermanên cûda çêtirîn dixebite.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation (PIH) is a common acquired cutaneous disorder occurring after skin inflammation or injury. It is chronic and is more common and severe in darker-skinned individuals (Fitzpatrick skin types III–VI). While the condition typically improves spontaneously, this process can take months to years, necessitating prolonged treatment. Combination therapy is the most effective.
Postinflammatory hyperpigmentation encamêk hevpar a iltîhabê çermê ye. Ew bi giranî û pir caran bandorê li kesên çermê tarî dike. Lêkolîn destnîşan dikin ku pirsgirêkên mîna postinflammatory hyperpigmentation di nav sedemên sereke de ne, û ku çima mirovên bi rengê çermê tarîtir lênihêrîna dermatolojîk digerin. Dermankirina zû ji bo çareserkirina postinflammatory hyperpigmentation girîng e û bi gelemperî bi birêvebirina rewşa destpêkê ya inflamatuar dest pê dike. Rêza yekem a dermankirinê bi gelemperî bi karanîna ajanên topkî yên ku çerm û tavê ronî dikin, ji bo parastinê vedihewîne. Van ajan, mîna hydroquinone, azelaic acid, kojic acid, arbutin, licorice extracts, dikarin bandora pigmentasyona zêde kêm bikin. Wekî din, retinoids, mequinol, ascorbic acid, niacinamide, N‑acetyl glucosamine, soy jî wekî ajanên depîgmentkirinê têne bikar anîn, digel ku dermankirinên nû derdikevin holê. Digel ku dermankirinên topkî bi gelemperî ji bo hîperpîgmentasyona asta rûkalê bandorker in, dibe ku prosedurên (laser, chemical peel) ji bo dozên serhişk hewcedar bin. Girîng e ku meriv bi van dermanan re hişyariyê bikar bîne da ku ji acizbûn û xirabbûna postinflammatory hyperpigmentation dûr nekeve.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
Postinflammatory hyperpigmentation is a common sequelae of inflammatory dermatoses that tends to affect darker skinned patients with greater frequency and severity. Epidemiological studies show that dyschromias, including postinflammatory hyperpigmentation, are among the most common reasons darker racial/ethnic groups seek the care of a dermatologist. The treatment of postinflammatory hyperpigmentation should be started early to help hasten its resolution and begins with management of the initial inflammatory condition. First-line therapy typically consists of topical depigmenting agents in addition to photoprotection including a sunscreen. Topical tyrosinase inhibitors, such as hydroquinone, azelaic acid, kojic acid, arbutin, and certain licorice extracts, can effectively lighten areas of hypermelanosis. Other depigmenting agents include retinoids, mequinol, ascorbic acid, niacinamide, N-acetyl glucosamine, and soy with a number of emerging therapies on the horizon. Topical therapy is typically effective for epidermal postinflammatory hyperpigmentation; however, certain procedures, such as chemical peeling and laser therapy, may help treat recalcitrant hyperpigmentation. It is also important to use caution with all of the above treatments to prevent irritation and worsening of postinflammatory hyperpigmentation.
